Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology in Drug Development
|
September 22, 2018
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
Michael A Tortorici, Danielle Duffy, Rebecca Evans, et al.
Clinical and Translational Science
|
August 11, 2017
Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
Richard L Dunbar, Rajesh Movva, LeAnne T Bloedon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 15, 2005
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
Philippe O Szapary, LeAnne T Bloedon, Frederick F Samaha, et al.
Clinical and Translational Science
|
August 7, 2022
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison
Bo Zheng, Shinya Goto, Regina Clementi, et al.
Journal of Lipid Research
|
March 8, 2008
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
Leanne T Bloedon, Richard Dunbar, Danielle Duffy, et al.
Frontiers in Cardiovascular Medicine
|
December 30, 2021
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
Jane J Lee, Gerald Chi, Clara Fitzgerald, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 30, 2023
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction
Svetlana A Didichenko, Elena Velkoska, Alexei V Navdaev, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 14, 2023
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Serge Korjian, Syed Hassan A Kazmi, Gerald Chi, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
October 25, 2022
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, et al.
JACC. Basic to Translational Science
|
April 30, 2025
Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport
Rommel A Mathias, Elena Velkoska, Svetlana A Didichenko, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology in Drug Development
|
September 22, 2018
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
Michael A Tortorici, Danielle Duffy, Rebecca Evans, et al.
Clinical and Translational Science
|
August 11, 2017
Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
Richard L Dunbar, Rajesh Movva, LeAnne T Bloedon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 15, 2005
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
Philippe O Szapary, LeAnne T Bloedon, Frederick F Samaha, et al.
Clinical and Translational Science
|
August 7, 2022
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison
Bo Zheng, Shinya Goto, Regina Clementi, et al.
Journal of Lipid Research
|
March 8, 2008
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
Leanne T Bloedon, Richard Dunbar, Danielle Duffy, et al.
Frontiers in Cardiovascular Medicine
|
December 30, 2021
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
Jane J Lee, Gerald Chi, Clara Fitzgerald, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 30, 2023
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction
Svetlana A Didichenko, Elena Velkoska, Alexei V Navdaev, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 14, 2023
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Serge Korjian, Syed Hassan A Kazmi, Gerald Chi, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
October 25, 2022
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, et al.
JACC. Basic to Translational Science
|
April 30, 2025
Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport
Rommel A Mathias, Elena Velkoska, Svetlana A Didichenko, et al.
Page
of 5